[{"orgOrder":0,"company":"Nanoform","sponsor":"Nacuity Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (\"PoC\") Agreement for Two Ophthalmic Drug Candidates","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Nanoform"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelSiTech Announces Positive Topline Clinical Data from Phase 1 Trial with its Sustained Release Eye Drop Platform","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"DelSiTech"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
DST-2105 is based on DelSiTech's Silica Matrix formulation technology which enables the once daily administration of eye drops in the cul-de-sac of the eye, which is investigated for relieving dry eye symptoms.
Nanoform and Nacuity have signed a Technology Proof of Concept Agreement. This will apply Nanoform’s award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates.